Next Article in Journal
Development of a Unified Reversed-Phase HPLC Method for Efficient Determination of EP and USP Process-Related Impurities in Celecoxib Using Analytical Quality by Design Principles
Previous Article in Journal
New Ionic Carbosilane Dendrons Possessing Fluorinated Tails at Different Locations on the Skeleton
Previous Article in Special Issue
Small Molecules Targeting the Specific Domains of Histone-Mark Readers in Cancer Therapy
Open AccessReview

Targeting Tumors Using Peptides

1
Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14B, Tartu 50411, Estonia
2
School of Science and Technology, National University of San Martin (UNSAM) and CONICET, Campus Migueletes, 25 de Mayo y Francia, San Martín, Buenos Aires CP 1650, Argentina
*
Author to whom correspondence should be addressed.
Molecules 2020, 25(4), 808; https://doi.org/10.3390/molecules25040808 (registering DOI)
Received: 20 January 2020 / Revised: 7 February 2020 / Accepted: 10 February 2020 / Published: 13 February 2020
(This article belongs to the Special Issue Peptides and Small Molecules as Anti-Cancer Agents)
To penetrate solid tumors, low molecular weight (Mw < 10 KDa) compounds have an edge over antibodies: their higher penetration because of their small size. Because of the dense stroma and high interstitial fluid pressure of solid tumors, the penetration of higher Mw compounds is unfavored and being small thus becomes an advantage. This review covers a wide range of peptidic ligands—linear, cyclic, macrocyclic and cyclotidic peptides—to target tumors: We describe the main tools to identify peptides experimentally, such as phage display, and the possible chemical modifications to enhance the properties of the identified peptides. We also review in silico identification of peptides and the most salient non-peptidic ligands in clinical stages. We later focus the attention on the current validated ligands available to target different tumor compartments: blood vessels, extracelullar matrix, and tumor associated macrophages. The clinical advances and failures of these ligands and their therapeutic conjugates will be discussed. We aim to present the reader with the state-of-the-art in targeting tumors, by using low Mw molecules, and the tools to identify new ligands. View Full-Text
Keywords: phage display; peptides; peptide-drug conjugates; small molecules; tumor associated macrophages; extracellular matrix phage display; peptides; peptide-drug conjugates; small molecules; tumor associated macrophages; extracellular matrix
Show Figures

Figure 1

MDPI and ACS Style

Scodeller, P.; Asciutto, E.K. Targeting Tumors Using Peptides. Molecules 2020, 25, 808.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop